Lam Research has clawed back from last week's sector-wide sell-off, and a wave of analyst target raises arriving almost simultaneously is reframing the Broadcom-driven drop as an entry point rather than a turning point.
The recovery sets up a genuine tension. LRCX closed at $327.16 on Tuesday, up 0.8% on the day and 11% higher than a month ago. The one-week return of -2.2% still reflects the aftershock of the 9.8% Thursday drop reported last week — but the stock has now retraced roughly half of that single-session loss. The question this week is whether the Street's freshly upgraded targets give the rally legs into the July 30 Q2 print.
The analyst picture has shifted materially in the past 48 hours. Cantor Fitzgerald's C.J. Muse raised his target from $320 to $425 on Tuesday morning, keeping an Overweight rating. UBS's Timothy Arcuri moved to $375 from $310 the day before. Both actions came after the sell-off, treating the dip as a reassessment opportunity rather than a structural warning. These follow Wells Fargo, Mizuho, and Morgan Stanley — which upgraded LRCX to Overweight in mid-May — all lifting targets across the past three weeks. The consensus price target now sits at $323.38, roughly in line with the current price, but the most active movers are clustered significantly above that average in the $365–$425 range, suggesting the consensus figure is being dragged up with a lag. The bull case is familiar: dominant etch and deposition share, TSMC and Micron exposure, and AI-driven demand for advanced memory. The bear case centers on export controls against China and any renewed softness in foundry capex.
Positioning tells a story of orderly caution rather than acute stress. Short interest has eased roughly 2% over the past week to 2.47% of the free float — a level too low to generate squeeze dynamics on its own. The borrow market is completely relaxed: availability is extremely wide, with over 9,000% of short interest available to lend, and cost to borrow is running at just 0.40%, down 16% from last week. Options are mildly defensive — the put/call ratio is 1.12, modestly above its 20-day average of 1.08 — but at less than one standard deviation above the mean, this is far from the charged hedging environment seen last week ahead of the Broadcom event. The ORTEX short score has drifted slightly lower over the past ten days to 33.6, consistent with a stock where short sellers are not building meaningful pressure.
Among peers, the picture is mixed but broadly stabilising. AMAT gained 1.9% on the week and KLAC added 4.6%, suggesting the more liquid equipment names have recovered faster. MKSI is still down 3.1% and MPWR is off 5.7%, pointing to lingering pockets of weakness in the group. LRCX at -2.2% on the week is roughly in the middle of the pack — neither a standout recovery nor still lagging badly.
The insider register is worth a mention for context. CFO Douglas Bettinger sold just over $29 million in shares across late February and early March at prices in the $222–$234 range — well below where the stock trades today. Those sales now look like pre-rally trimming rather than a signal about fundamentals. More recent insider activity from SVP Neil Fernandes in May and June has been smaller in scale and routine in character.
What to watch next: with Q2 results scheduled for July 30, the next six weeks will increasingly focus on whether the chip-equipment spending cycle — particularly from memory customers — is holding up at the pace embedded in those freshly raised price targets.
See the live data behind this article on ORTEX.
Open LRCX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
